- Home
- BESS vs QNCX Comparison
BESS vs QNCX Comparison
Compare BESS & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BESS | QNCX |
|---|---|---|
| Founded | 1998 | 2012 |
| Country | United States | United States |
| Employees | 3 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.9M | 19.9M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | BESS | QNCX |
|---|---|---|
| Price | $2.30 | $1.24 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 29.6K | ★ 55.2M |
| Earning Date | 03-31-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.06 | $0.08 |
| 52 Week High | $3.60 | $4.55 |
Technical Indicators
Market Signals| Indicator | BESS | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 37.87 | 63.72 |
| Support Level | $2.06 | $1.17 |
| Resistance Level | $3.04 | $1.50 |
| Average True Range (ATR) | 0.24 | 0.12 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 2.70 | 18.06 |
Price Performance
Historical ComparisonAbout BESS Bimergen Energy Corporation Common Stock
Bimergen Energy Corp is a renewable energy project developer that enables the clean energy transition and provides critical grid stability via solutions across a range of applications through portfolio of utility-scale Battery Energy Storage System (BESS) and solar development projects. Its portfolio includes approximately 23 development-stage utility-scale BESS projects with a projected total storage capacity of around 1.965 gigawatts (GW) and approximately 13 development-stage solar energy projects expected to generate around 1.640 GW upon completion and operation.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.